Given the recent use of anti-CD20 therapies in treating MS and other neuroinflammatory diseases, few studies have been published that address their tolerability and safety outcomes in a real-world cohort of pwMS (2, 15–18). The gene discussed is MS4A1; the disease is myeloid sarcoma.